69 related articles for article (PubMed ID: 31401678)
1. CYP3A genes and the association between prenatal methylmercury exposure and neurodevelopment.
Llop S; Tran V; Ballester F; Barbone F; Sofianou-Katsoulis A; Sunyer J; Engström K; Alhamdow A; Love TM; Watson GE; Bustamante M; Murcia M; Iñiguez C; Shamlaye CF; Rosolen V; Mariuz M; Horvat M; Tratnik JS; Mazej D; van Wijngaarden E; Davidson PW; Myers GJ; Rand MD; Broberg K
Environ Int; 2017 Aug; 105():34-42. PubMed ID: 28500872
[TBL] [Abstract][Full Text] [Related]
2. A Machine Learning-Based Identification of Genes Affecting the Pharmacokinetics of Tacrolimus Using the DMET
Gim JA; Kwon Y; Lee HA; Lee KR; Kim S; Choi Y; Kim YK; Lee H
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260456
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Toxicity of Vincristine and CYP3A5 Genetic Polymorphism in Rhabdomyosarcoma Pediatric Egyptian Patients.
Shalaby N; Zaki HF; Badary OA; Kamal S; Nagy M; Makhlouf D; Elnashar A; Elnadi E; Abdelshafi SA; Abouelnaga S; Saber MM
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1391-1409. PubMed ID: 38680001
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer.
Johnson N; De Ieso P; Migliorini G; Orr N; Broderick P; Catovsky D; Matakidou A; Eisen T; Goldsmith C; Dudbridge F; Peto J; Dos-Santos-Silva I; Ashworth A; Ross G; Houlston RS; Fletcher O
Cancer Res; 2016 Mar; 76(6):1485-1493. PubMed ID: 26964624
[TBL] [Abstract][Full Text] [Related]
5. Single-Nucleotide Polymorphisms Associated with Mercury Levels and Neurological Symptoms: An Overview.
Perini JA; Cardoso JV; Knesse AO; Pessoa-Silva FO; Vasconcellos ACS; Machado DE; Basta PC
Toxics; 2024 Mar; 12(3):. PubMed ID: 38535959
[TBL] [Abstract][Full Text] [Related]
6. Optimization of initial dosing scheme of tacrolimus in pediatric refractory nephrotic syndrome patients based on CYP3A5 genotype and coadministration with wuzhi-capsule.
Chen X; Wang DD; Xu H; Li ZP
Xenobiotica; 2020 May; 50(5):606-613. PubMed ID: 31530218
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model.
Huang L; Liu Y; Jiao Z; Wang J; Fang L; Mao J
Eur J Pharm Sci; 2020 Feb; 143():105199. PubMed ID: 31862313
[TBL] [Abstract][Full Text] [Related]
8. Genotypic and phenotypic landscapes of 51 pharmacogenes derived from whole-genome sequencing in a Thai population.
Wankaew N; Chariyavilaskul P; Chamnanphon M; Assawapitaksakul A; Chetruengchai W; Pongpanich M; Shotelersuk V
PLoS One; 2022; 17(2):e0263621. PubMed ID: 35176049
[TBL] [Abstract][Full Text] [Related]
9. Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients.
Job KM; Roberts JK; Enioutina EY; Illamola SM; Kumar SS; Rashid J; Ward RM; Fukuda T; Sherbotie J; Sherwin CM
Expert Opin Drug Metab Toxicol; 2021 Jul; 17(7):747-765. PubMed ID: 34121566
[No Abstract] [Full Text] [Related]
10. Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates.
Saiz-Rodríguez M; Almenara S; Navares-Gómez M; Ochoa D; Román M; Zubiaur P; Koller D; Santos M; Mejía G; Borobia AM; Rodríguez-Antona C; Abad-Santos F
Biomedicines; 2020 Apr; 8(4):. PubMed ID: 32331352
[TBL] [Abstract][Full Text] [Related]
11. Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms.
Wang J; Huang L; Gao P; Hu Y; Ni Y; Zhu Z; Zhang L; Yang J; Zhang H; Fang L
Eur J Clin Pharmacol; 2021 Jan; 77(1):71-77. PubMed ID: 32803289
[TBL] [Abstract][Full Text] [Related]
12. Effects of CYP3A5 polymorphisms on tacrolimus pharmacokinetics in pediatric kidney transplantation: a systematic review and meta-analysis of observational studies.
Zong YP; Wang ZJ; Zhou WL; Zhou WM; Ma TL; Huang ZK; Zhao CC; Xu Z; Tan RY; Gu M
World J Pediatr; 2017 Oct; 13(5):421-426. PubMed ID: 28540692
[TBL] [Abstract][Full Text] [Related]
13. Individualized Tacrolimus Therapy for Pediatric Nephrotic Syndrome: Considerations for Ontogeny and Pharmacogenetics of CYP3A.
Sun JY; Xu ZJ; Sun F; Guo HL; Ding XS; Chen F; Xu J
Curr Pharm Des; 2018; 24(24):2765-2773. PubMed ID: 30156148
[TBL] [Abstract][Full Text] [Related]
14. CYP3A5 and CYP3A7 genetic polymorphisms affect tacrolimus concentration in pediatric patients with nephrotic range proteinuria.
Liu H; Xu Q; Huang W; Zhao Q; Jiang Z; Kuang X; Li Z; Sun H; Qiu X
Eur J Clin Pharmacol; 2019 Nov; 75(11):1533-1540. PubMed ID: 31401678
[TBL] [Abstract][Full Text] [Related]
15. CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation.
Dong Y; Xu Q; Li R; Tao Y; Zhang Q; Li J; Ma Z; Shen C; Zhong M; Wang Z; Qiu X
Gene; 2022 Jan; 809():146007. PubMed ID: 34688813
[TBL] [Abstract][Full Text] [Related]
16. Whole exome sequencing for the identification of CYP3A7 variants associated with tacrolimus concentrations in kidney transplant patients.
Sohn M; Kim MG; Han N; Kim IW; Gim J; Min SI; Song EY; Kim YS; Jung HS; Shin YK; Ha J; Oh JM
Sci Rep; 2018 Dec; 8(1):18064. PubMed ID: 30584253
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
